|
1
|
Leslie SW, Sajjad H and Murphy PB: Wilms
Tumor (Nephroblastoma). StatPearls; Treasure Island, FL: 2019
|
|
2
|
Anderson TE and Conran RM: Educational
case: Wilms tumor (Nephroblastoma). Acad Pathol.
6:23742895188213812019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang L, Gao X, Zhou X, Qin Z, Wang Y, Li
R, Tang M, Wang W and Zhang W: Identification of key genes and
microRNAs involved in kidney wilms tumor by integrated
bioinformatics analysis. Exp Ther Med. 18:2554–2564.
2019.PubMed/NCBI
|
|
4
|
Chakumatha E, Weijers J, Banda K, Bailey
S, Molyneux E, Chagaluka and Israels T: Outcome at the end of
treatment of patients with common and curable childhood cancer
types in Blantyre, Malawi. Pediatr Blood Cancer. 67:e283222020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lamb MG, Aldrink JH, O'Brien SH, Yin H,
Arnold MA and Ranalli MA: Renal tumors in children younger than 12
months of Age: A 65-year single institution review. J Pediatr
Hematol Oncol. 39:103–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Illhardt T, Ebinger M, Schwarze CP,
Feuchtinger T, Furtwangler R, Schlegel PG, Klingebiel T, Greil J,
Beck JF, Handgretinger R and Lang P: Children with relapsed or
refractory nephroblastoma: Favorable long-term survival after
high-dose chemotherapy and autologous stem cell transplantation.
Klin Padiatr. 226:351–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weirich A, Ludwig R, Graf N, Abel U,
Leuschner I, Vujanic GM, Mehls O, Boos J, Beck J, Royer-Pokora B
and Voûte PA: Survival in nephroblastoma treated according to the
trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Ann Oncol. 15:808–820. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi C, Shi R, Guo H, Shi Y and Liu X:
β-amyloid-induced gonadotropin-releasing hormone decline involving
forkhead transcription factor FOXO3a and nuclear factor-κB.
Neuroreport. 31:923–927. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Q, Tang H, Hu F and Qin C: Silencing of
FOXO6 inhibits the proliferation, invasion, and glycolysis in
colorectal cancer cells. J Cell Biochem. 120:3853–3860. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Menghini R, Casagrande V, Iuliani G, Rizza
S, Mavilio M, Cardellini M and Federici M: Metabolic aspects of
cardiovascular diseases: Is FoxO1 a player or a target? Int J
Biochem Cell Biol. 118:1056592020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu W, Li Y and Luo B: Current perspective
on the regulation of FOXO4 and its role in disease progression.
Cell Mol Life Sci. 7:651–663. 2019.
|
|
12
|
Usami M, Kikuchi S, Takada K, Ono M,
Sugama Y, Arihara Y, Hayasaka N, Nakamura H, Ikeda Y, Hirakawa M,
et al: FOXO3a activation by HDAC class IIa inhibition induces cell
cycle arrest in pancreatic cancer cells. Pancreas. 49:135–142.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Belguise K, Guo S and Sonenshein GE:
Activation of FOXO3a by the green tea polyphenol
epigallocatechin-3-gallate induces estrogen receptor alpha
expression reversing invasive phenotype of breast cancer cells.
Cancer Res. 67:5763–5770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou
J, Li L, Chen Y, Zhang T, Wang X, et al: PI3K/Akt to
GSK3beta/beta-catenin signaling cascade coordinates cell
colonization for bladder cancer bone metastasis through regulating
ZEB1 transcription. Cell Signal. 24:2273–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ni D, Ma X, Li HZ, Gao Y, Li XT, Zhang Y,
Ai Q, Zhang P, Song EL, Huang QB, et al: Downregulation of FOXO3a
promotes tumor metastasis and is associated with metastasis-free
survival of patients with clear cell renal cell carcinoma. Clin
Cancer Res. 20:1779–1790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ramis G, Villalonga-Planells R,
Serra-Sitjar M, Brell M, Fernandez de Mattos S and Villalonga P:
The tumor suppressor FOXO3a mediates the response to EGFR
inhibition in glioblastoma cells. Cell Oncol (Dordr). 42:521–536.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Yang R, Dong Y, Chen M, Wang Y and
Wang G: Knockdown of FOXO3a induces epithelial-mesenchymal
transition and promotes metastasis of pancreatic ductal
adenocarcinoma by activation of the β-catenin/TCF4 pathway through
SPRY2. J Exp Clin Cancer Res. 38:382019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen H, Xu L and Wang L: Expression of
miR-182 and Foxo3a in patients with bladder cancer correlate with
prognosis. Int J Clin Exp Pathol. 12:4193–4203. 2019.PubMed/NCBI
|
|
19
|
Zhao R, Li Y, Gorantla S, Poluektova LY,
Lin H, Gao F, Wang H, Zhao J, Zheng JC and Huang Y: Small molecule
ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and
TRAIL. Antiviral Res. 168:134–145. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao W, Li J, Li P, Guo F, Gao P, Zhang J,
Yan Z, Wang L, Zhang D and Qin P: Wilms tumor-suppressing peptide
inhibits proliferation and induces apoptosis of Wilms tumor cells
in vitro and in vivo. J Cancer Res Clin Oncol. 145:2457–2468. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nitulescu GM, Van De Venter M, Nitulescu
G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis
A, Tsoukalas D, et al: The Akt pathway in oncology therapy and
beyond (Review). Int J Oncol. 53:2319–2331. 2018.PubMed/NCBI
|
|
22
|
Lachmandas E, Beigier-Bompadre M, Cheng
SC, Kumar V, van Laarhoven A, Wang X, Ammerdorffer A, Boutens L, de
Jong D, Kanneganti TD, et al: Rewiring cellular metabolism via the
AKT/mTOR pathway contributes to host defence against Mycobacterium
tuberculosis in human and murine cells. Eur J Immunol.
46:2574–2586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qian J, Huang X, Zhang Y, Ye X and Qian W:
γ-catenin overexpression in AML patients may promote tumor cell
survival via activation of the wnt/beta-catenin axis. Onco Targets
Ther. 13:1265–1276. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu
X, Meeth K, Sahraei M, Bothwell AL, Chen L, et al: DKK2 imparts
tumor immunity evasion through beta-catenin-independent suppression
of cytotoxic immune-cell activation. Nat Med. 24:262–270. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anton R, Chatterjee SS, Simundza J, Cowin
P and Dasgupta R: A systematic screen for micro-RNAs regulating the
canonical wnt pathway. PLoS One. 6:e262572011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Re GG, Hazen-Martin DJ, Sens DA and Garvin
AJ: Nephroblastoma (Wilms' tumor): A model system of aberrant renal
development. Semin Diagn Pathol. 11:126–135. 1994.PubMed/NCBI
|
|
27
|
Hu Z, Li L, Cheng P, Liu Q, Zheng X, Peng
F and Zhang Q: lncRNA MSC-AS1 activates Wnt/β-catenin signaling
pathway to modulate cell proliferation and migration in kidney
renal clear cell carcinoma via miR-3924/WNT5A. J Cell Biochem.
121:4085–4093. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rim EY, Kinney LK and Nusse R:
β-catenin-mediated wnt signal transduction proceeds through an
endocytosis-independent mechanism. Mol Biol Cell. 31:1425–1436.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haque I, Banerjee S, Mehta S, De A,
Majumder M, Mayo MS, Kambhampati S, Campbell DR and Banerjee SK:
Cysteine-rich 61-connective tissue growth
factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced
signaling protein-2 (WISP-2) regulates microRNA-10b via
hypoxia-inducible factor-1α-TWIST signaling networks in human
breast cancer cells. J Biol Chem. 286:43475–43485. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fair D, Potter SL and Venkatramani R:
Challenges and solutions to the study of rare childhood tumors.
Curr Opin Pediatr. 32:7–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chong WC and Cain JE: Lessons learned from
the developmental origins of childhood renal cancer. Anat Rec
(Hoboken). 303:2561–2577. 2020. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hang S, Wang X and Li H: Triptolide
inhibits viability and migration while promotes apoptosis in
nephroblastoma cells by regulation of miR-193b-3p. Exp Mol Pathol.
108:80–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Ren SY, Qu Y, Liu C, Zhang Y, Li XQ
and Ma H: MiR-194-5p inhibited metastasis and EMT of nephroblastoma
cells through targeting Crk. Kaohsiung J Med Sci. 36:265–273. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakabayashi A, Kanno T, Takahashi N,
Akizawa Y, Onizuka H and Matsui H: A case of ovarian teratoma with
nephroblastoma presenting spontaneous rupture. J Obstet Gynaecol
Res. 45:1079–1083. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bellalah A, Abdeljelil NB, Njima M,
Hamdani M, Hamdouni W, Hadhri R, Moussa A, Zakhama A and Njim L:
Fetal rhabdomyomatous nephroblastoma in a 31-year-old woman: A case
report. Urology. 133:e5–e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu Y and Yan J: Aberrant expression and
mechanism of miR-130b-3p/phosphatase and tensin homolog in
nephroblastoma in children. Exp Ther Med. 18:1021–1028.
2019.PubMed/NCBI
|
|
38
|
Jones BC, Youlden DR, Cundy TP,
O'Callaghan ME, Karpelowsky J, Aitken JF and Mcbride CA: Renal
tumours in Australian children: 30 years of incidence, outcome and
second primary malignancy data from the Australian childhood cancer
registry. J Paediatr Child Health. 56:908–916. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pomponio MK, Burkbauer L, Goldbach M,
Nazarian SM, Xie F, Clark AS, Matro JM, Fox KR, Shulman LN, Keele
LJ and Tchou J: Refining the indications for neoadjuvant
chemotherapy for patients with HER2+ breast cancer: A single
institution experience. J Surg Oncol. 121:447–455. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang X, Su D, Qin Z and Chen Z:
Identification of FOXN4 as a tumor suppressor of breast
carcinogenesis via the activation of TP53 and deactivation of notch
signaling. Gene. 722:1440572020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Strassheim D, Karoor V, Nijmeh H, Weston
P, Lapel M, Schaack J, Sullivan T, Dempsey EC, Stenmark KR and
Gerasimovskaya E: c-Jun, Foxo3a, and c-Myc transcription factors
are key regulators of ATP-mediated angiogenic responses in
pulmonary artery vasa vasorum endothelial cells. Cells. 9:4162020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Grossi V, Fasano C, Celestini V, Signorile
ML, Sanese P and Simone C: Chasing the FOXO3: Insights into its new
mitochondrial lair in colorectal cancer landscape. Cancers (Basel).
11:4142019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vasickova K, Horak P and Vanhara P: TUSC3:
functional duality of a cancer gene. Cell Mol Life Sci. 75:849–857.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yue X, Zhang C, Zhao Y, Liu J, Lin AW, Tan
VM, Drake JM, Liu L, Boateng MN, Li J, et al: Gain-of-function
mutant p53 activates small GTPase Rac1 through SUMOylation to
promote tumor progression. Genes Dev. 31:1641–1654. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pang X, Zhou Z, Yu Z, Han L, Lin Z, Ao X,
Liu C, He Y, Ponnusamy M, Li P and Wang J: Foxo3a-dependent miR-633
regulates chemotherapeutic sensitivity in gastric cancer by
targeting fas-associated death domain. RNA Biol. 16:233–248. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ge YF, Sun J, Jin CJ, Cao BQ, Jiang ZF and
Shao JF: AntagomiR-27a targets FOXO3a in glioblastoma and
suppresses U87 cell growth in vitro and in vivo. Asian Pac J Cancer
Prev. 14:963–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y,
Jiang G, Lu M, Zhang Z, Yin J, et al: Downregulation of FOXO3a by
DNMT1 promotes breast cancer stem cell properties and
tumorigenesis. Cell Death Differ. 27:966–983. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jin L, Zhang J, Fu HQ, Zhang X and Pan YL:
FOXO3a inhibits the EMT and metastasis of breast cancer by
regulating TWIST-1 mediated miR-10b/CADM2 axis. Transl Oncol.
14:1010962021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang X, Chen Z, Shi W, Zhang R, Li L, Liu
H and Wu L: TMF inhibits miR-29a/Wnt/β-catenin signaling through
upregulating Foxo3a activity in osteoarthritis chondrocytes. Drug
Des Devel Ther. 13:2009–2019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sun T, Zhang J, Deng B, Fan X, Long T, Jin
H, Tao S, Kang P and Tan Q: FOXO1 and FOXO3a sensitize
non-small-cell lung cancer cells to cisplatin-induced apoptosis
independent of Bim. Acta Biochim Biophys Sin. 52:1348–1359. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhu Z, Zhang H, Lang F, Liu G, Gao S, Li B
and Liu Y: Pin1 promotes prostate cancer cell proliferation and
migration through activation of Wnt/beta-catenin signaling. Clin
Transl Oncol. 18:792–797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kotrbova A, Ovesna P, Gybel T,
Radaszkiewicz T, Bednaříková M, Hausnerová J, Jandáková E, Minář L,
Crha I, Weinberger V, et al: WNT signaling inducing activity in
ascites predicts poor outcome in ovarian cancer. Theranostics.
10:537–552. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang Y, Liang SH, Xiang LB, Han XT, Zhang
W, Tang J, Wu XH and Zhan MQ: miR-218 promoted the apoptosis of
human ovarian carcinoma cells via suppression of the
WNT/beta-catenin signaling pathway. Mol Biol (Mosk). 51:629–636.
2017.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Han XF, Zhang XX, Liu KM and Zhang Q:
Apelin-13 deficiency alters cortical bone geometry, organic bone
matrix, and inhibits Wnt/β-catenin signaling. Gen Comp Endocrinol.
267:29–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
